Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs).
September 16, 2025 | 2025 EDIT PUBLISH, Creative and Design, Digital Communications, Equitable access, Health policy and government affairs, Market Access, Medical Communications, Patient support and adherence, Sales October 22 September 8, cell and gene therapy, clinical research, medical education, pharmacy, regulatory affairs
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs).
This content was provided by Uniphar
Latest Content from Uniphar
Isaac Batley, an experienced CEO with 35 years’ experience within healthcare and pharmaceutical communications, joins Uniphar to spearhead its medical communications division.
Healthcare services business, Uniphar, has developed its full-service offering that harnesses Uniphar’s 57 years in the industry delivering specialist services to more than 200 international clients across 180 countries.
